|
| Index | - | P/E | - | EPS (ttm) | -1.56 | Insider Own | 2.80% | Shs Outstand | 48.80M | Perf Week | -4.24% |
| Market Cap | 77.00M | Forward P/E | - | EPS next Y | -0.12 | Insider Trans | 0.00% | Shs Float | 48.15M | Perf Month | -13.74% |
| Income | -25.80M | PEG | - | EPS next Q | -0.07 | Inst Own | 7.50% | Short Float | 3.14% | Perf Quarter | 2.73% |
| Sales | 1.20M | P/S | 64.17 | EPS this Y | 67.70% | Inst Trans | 2.08% | Short Ratio | 0.53 | Perf Half Y | 8.65% |
| Book/sh | 0.97 | P/B | 1.16 | EPS next Y | 59.30% | ROA | -97.90% | Target Price | - | Perf Year | -26.14% |
| Cash/sh | 0.40 | P/C | 2.82 | EPS next 5Y | - | ROE | -166.10% | 52W Range | 0.63 - 2.30 | Perf YTD | 54.29% |
| Dividend | - | P/FCF | - | EPS past 5Y | 62.80% | ROI | -390.80% | 52W High | -50.87% | Beta | 1.97 |
| Dividend % | - | Quick Ratio | 8.60 | Sales past 5Y | 13.90% | Gross Margin | 63.50% | 52W Low | 79.37% | ATR | 0.08 |
| Employees | 22 | Current Ratio | 8.60 | Sales Q/Q | 0.00% | Oper. Margin | - | RSI (14) | 46.25 | Volatility | 4.12% 7.40% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 88.50% | Profit Margin | - | Rel Volume | 0.22 | Prev Close | 1.16 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 2.83M | Price | 1.13 |
| Recom | 2.00 | SMA20 | -4.07% | SMA50 | -4.74% | SMA200 | 2.94% | Volume | 621,766 | Change | -2.59% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite